Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 34Recruiting 19Terminated 4Not yet recruiting 3Completed 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Specimen Handling 76Cisplatin 64Drug Therapy 63Carboplatin 63Bevacizumab 63Magnetic Resonance Spectroscopy 59Radiotherapy 57Gemcitabine 54Cyclophosphamide 54pembrolizumab 52Oxaliplatin 49Capecitabine 49toripalimab 44Paclitaxel 40tislelizumab 39Standard of Care 39fludarabine 36Injections 34Fluorouracil 34Biopsy 34venetoclax 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 28Nivolumab 28Surgical Procedures, Operative 27Irinotecan 27Docetaxel 27Leucovorin 26Dexamethasone 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × CT-P10 × 1 year × Clear all
NCT07583810 2026-05-15

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
16 enrolled
Lymphoid

Ann Arbor Stage II Mantle Cell Lymphoma

NCT07578077 2026-05-11

Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Not yet recruiting
58 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡